Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson & Johnson (JNJ) announced that sales of the oncology drug Darzalex rose over 20% in the first quarter of 2025.
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
Genmab licensed daratumumab to Johnson & Johnson unit Janssen Biotech, Inc. in August 2012.
Darzalex is a prescription medication used to treat multiple myeloma, a type of blood cancer. For the three months through the end of March, Johnson & Johnson reported sales of $3.24 billion for Darzalex, marking a growth of 20.3% year-on-year.
Darzalex accounted for over 23% of the company’s overall sales in its innovative medicine segment and nearly 15% of its overall reported sales.
Darzalex sales in the U.S. jumped 25% to $1.83 billion during the quarter, while sales outside the country jumped 15% to $1.41 billion.
The rise in Darzalex sales enabled the company to offset the 34% drop in sales of its immunology drug Stelara to $1.63 billion.
On Stocktwits, retail sentiment around Genmab fell marginally while staying within ‘extremely bullish’ territory over the past 24 hours, while message volume dropped to ‘extremely low’ levels.
A Stocktwits user opined that Genmab shares are cheap.
https://stocktwits.com/Pika_Capital/message/611668890
GMAB stock fell by about 7% year-to-date and over 33% over the past 12 months.
Also See: Dow Jones Futures Tick Higher As Investors Await Earnings, Monitor Tariff Developments
For updates and corrections, email newsroom[at]stocktwits[dot]com